Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Pouya Safarzadeh, Kozani"'
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Background The immunogenicity of the antigen-recognition domains of chimeric antigen receptor (CAR)-T cells leads to immune responses that may compromise the antitumor effects of the adoptively transferred T cells. Herein, we attempt to huma
Externí odkaz:
https://doaj.org/article/b40d894e8b4549109a152c136e21a087
Autor:
Fatemeh Nasiri, Khadijeh Farrokhi, Pouya Safarzadeh Kozani, Maral Mahboubi Kancha, Setareh Dashti Shokoohi, Pooria Safarzadeh Kozani
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
As the most lethal gynecologic oncological indication, carcinoma of the ovary has been ranked as the 5th cause of cancer-related mortality in women, with a high percentage of the patients being diagnosed at late stages of the disease and a five-year
Externí odkaz:
https://doaj.org/article/07d4872d3249430ca2fa9ebf53f96b9b
Autor:
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, Faeze Salem, Mojtaba Nikbakht, Sahar Evazi Bakhshi, Pooria Safarzadeh Kozani
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-18 (2022)
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy has been successful in treating various types of hematological cancers
Externí odkaz:
https://doaj.org/article/107067e0420e4f838aac2ceeeda3e098
Publikováno v:
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-17 (2021)
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic
Externí odkaz:
https://doaj.org/article/f143fe4da184406cb8c18faa2ee251bc
Autor:
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) exp
Externí odkaz:
https://doaj.org/article/0fd5903bd8554f308dca89242ee7a86d
Publikováno v:
Exploration of Medicine, Vol 2, Iss 2, Pp 146-166 (2021)
Nucleolin (NCL) is a multifunctional nucleolar phosphoprotein harboring critical roles in cells such as cell proliferation, survival, and growth. The dysregulation and overexpression of NCL are related to various pathologic and oncological indication
Externí odkaz:
https://doaj.org/article/be66329843aa42cab52f317b09f43920
Autor:
Mehdi Evazalipour, Sana Moayedi, Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Ehsan Zamani
Publikováno v:
Research Journal of Pharmacognosy, Vol 8, Iss 1, Pp 19-27 (2021)
Background and Objectives: Carvacrol is a natural antioxidant possessing various biological properties. Diphenhydramine is a first-generation antihistamine prescribed for allergies and the common cold. Recently, investigations have shown that diphenh
Externí odkaz:
https://doaj.org/article/37578a8efbee47699896b8f4a423ea54
Autor:
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Milad Ahmadi Najafabadi, Fatemeh Yousefi, Seyed Mohamad Javad Mirarefin, Fatemeh Rahbarizadeh
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large
Externí odkaz:
https://doaj.org/article/b76c836018194667bee947ab40f244be
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chimeric antigen receptor T-cell (CAR-T) therapy has been successful in creating extraordinary clinical outcomes in the treatment of hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). With sev
Externí odkaz:
https://doaj.org/article/0b91abd0e92f4f25ae9a54eaa679b4cb
Publikováno v:
Translational Oncology, Vol 14, Iss 7, Pp 101079- (2021)
Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple mye
Externí odkaz:
https://doaj.org/article/48ad8659d2934b6a97124432bd81ffb4